- 25 **Fitzgerald RC**, Omary MB, Triadafilopoulos G. Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus. *J Cell Sci* 1997;**110**:663–71.
- 26 **Mosmann T**. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 1983;**65**:55–63.
- 27 **Tang YKV**, Srinivasan R, Fogt F, et al. Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. *Cancer Res* 2004;**65**:4228–37.
- 28 **Okano HSH**, Miyamoto A, Takaori K, et al. Concomitant overexpression of cyclooxygenase-2 in HER-2-positive on Smad4-reduced human gastric carcinomas is associated with a poor patient outcome. *Clin Cancer Res* 2004;**10**:6938–45.
- 29 **Lazzereschi DNF**, Turco A, Ottini L, et al. A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. *Oncogene* 2005;**24**:5344–54.
- 30 **Xu X**, Brodie SG, Yang X, et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. *Oncogene* 2000;**19**:1868–74.
- 31 **Jazag AH**, Kanai F, Imamura T, et al. Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. *Oncogene* 2005;**24**:662–71.
- 32 **Zhou Y**, Kato H, Shan D, et al. Involvement of mutations in the DPC4 promoter in endometrial carcinoma development. *Mol Carcinog* 1999;**25**:64–72.
- 33 **Saha D**, Datta PK, Beauchamp RD. Oncogenic ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4. *J Biol Chem* 2001;**276**:29531–7.
- 34 **Galiana C**, Lozano JC, Bancel B, et al. High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus. *Mol Carcinog* 1995;**14**:286–93.
- 35 **Bai RY**, Koester C, Ouyang T, et al. SMIF, a Smad4-interacting protein that functions as a co-activator in TGFbeta signalling. *Nat Cell Biol* 2002;**4**:181–90.
- 36 **Wan M**, Cao X, Wu Y, et al. Jab1 antagonizes TGF-beta signaling by inducing Smad4 degradation. *EMBO Rep* 2002;**3**:171–6.
- 37 **Lin X**, Liang M, Liang YY, et al. SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. *J Biol Chem* 2003;**278**:31043–8.
- 38 **Lin X**, Liang M, Liang YY, et al. Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4. *J Biol Chem* 2003;**278**:18714–9.
- 39 **Lee PS**, Chang C, Liu D, et al. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. *J Biol Chem* 2003;**278**:27853–63.
- 40 **Muller N**, Reinacher-Schick A, Baldus S, et al. Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells. *Oncogene* 2002;**21**:6049–58.
- 41 **Ijichi H**, Ikenoue T, Kato N, et al. Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells. *Biochem Biophys Res Commun* 2001;**289**:350–7.

EDITOR'S QUIZ: GI SNAPSHOT

Intermittent fever in a patient with apparent fatty liver

Robin Spiller, Editor

Clinical presentation

A 41 year old female presented with non-specific abdominal pain and intermittent hyperpyrexia (38°C); she had been recently treated for apical granulomas with an otherwise negative medical history and clinical examination, including a normal body mass index. At presentation the patient had not received any medication for the past two weeks.

Laboratory investigations were within normal limits apart from: erythrocyte sedimentation rate 30 mm (normal range 5–20), aspartate aminotransferase/alanine aminotransferase 49/62 U/l (normal range 13–37/7–43), and serum alkaline phosphatase 168 U/l (normal range 44–132). Blood cultures were negative.

A chest x ray revealed no lesion and liver sonography demonstrated a patchy hypo-hyper-echoic polycyclic area in the anterior-superior parenchyma compatible with segmental fatty liver. Thoracic abdominal contrastographic computed tomography confirmed a large regular polycyclic borders area, hypodense compared with the remaining parenchyma, with no mass effect and/or any displacement of the vessels, resembling focal fatty areas (fig 1A, B); no other pathological

signs were found except for small lymphadenopathies adjacent to frenal pillars.

Question

Is it really fatty liver? What is your diagnosis?

See page 823 for answer

This case is submitted by:

S Colagrande

Sezione di Radiodiagnostica, Dipartimento di Fisiopatologia Clinica, Italy

S Santini

Azienda Ospedaliera USL 11-Ospedale San Giuseppe, Firenze, Italy

M Pinzani

Dipartimento di Medicina Interna, Università degli Studi di Firenze, Azienda Ospedaliero-Universitaria di Careggi, Firenze, Italy

Correspondence to: Professor S Colagrande, Sezione di Radiodiagnostica, Dipartimento di Fisiopatologia Clinica, Università degli Studi di Firenze, Azienda Ospedaliero-Universitaria di Careggi, Viale Morgagni 85, 50134 Firenze (FI), Italy; stefano.colagrande@unifi.it

doi: 10.1136/gut.2005.078378

Figure 1 Direct (A) and iodinated (B) spiral computed tomography scans revealed regular polycyclic borders area (white arrows), hypodense compared with remaining parenchyma, with no mass effect and/or any displacement of the parenchymal vessels.